Baker Brothers portfolio, Q4 2025

Baker Bros. Advisors · 13F for the quarter ending Dec 31, 2025

For Q4 2025, Baker Bros. Advisors reported $17.1B across 86 US-listed positions, led by INCY (17.8%), ONC (15.7%) and MDGL (7.3%). Compared with its filing for Q3 2025, Baker Brothers opened 9 new positions, added to 23, reduced 7 and sold out of 14; 47 positions did not change.

The largest purchase was an addition to KYMR ($156.1M); the largest sale, the sale of the whole position in Merus N V ($54.1M).

Reported value
$17.1B
Positions
86
In the top 10
74%
Filed
Feb 17
2026

Key facts

13F portfolio value
$17.1BQ4 2025
Positions
86
Largest holding
INCY 17.8%
New positions
9
Sold out
14
Filed
Feb 17, 2026

Holdings as of (Q4 2025), filed with the SEC on . Changes are measured against the filing for Sep 30, 2025. Every tracked investor's Q4 2025 13F.

Bought and sold in Q4 2025

Baker Brothers: buys and sells in Q4 2025
StockMoveSharesSizeOf portfolio
Kymera Therapeutics IncKYMR▲ Added 30%+2.01M$156.1M0.91%
Praxis Precision MedicinesPRAX▲ Added 63%+437K$128.8M0.75%
Ionis Pharmaceuticals IncIONS▲ Added 216%+1.23M$96.9M0.57%
Kodiak Sciences IncKOD▲ Added 15%+2.61M$72.9M0.43%
Crinetics Pharmaceuticalsno ticker on file
▲ Added 489%+1.37M$63.7M0.37%
Merus N Vno ticker on file
▼ Sold out−574.38K$54.1M0.32%
Alkermes PLCALKS▲ Added 24%+1.92M$53.7M0.31%
Intellia Therapeutics IncNTLA▼ Sold out−2.75M$47.4M0.28%
Summit Therapeutics IncSMMT▲ Added 7.9%+2.67M$46.7M0.27%
Stoke Therapeutics IncSTOK▼ Reduced 28%−1.3M$41.2M0.24%
Grail IncGRAL▲ Added 28%+455.21K$39M0.23%
Roivant Sciences LtdROIV▲ Added 47%+1.79M$38.8M0.23%
Terns Pharmaceuticals Incno ticker on file
▲ New+950K$38.4M0.22%
Arrowhead PharmaceuticalsARWR▲ Added 30%+504.88K$33.5M0.20%
Avidity Biosciences Incno ticker on file
▼ Sold out−625K$27.2M0.16%
Jade Biosciences IncJBIO▲ New+1.64M$25.3M0.15%
Vaxcyte IncPCVX▼ Sold out−640.89K$23.1M0.14%
BioCryst Pharmaceuticals IncBCRX▲ New+2.82M$22M0.13%
Cidara Therapeutics Incno ticker on file
▼ Sold out−227.27K$21.8M0.13%
Insmed IncINSM▼ Reduced 1.7%−110.74K$19.3M0.11%
Edgewise Therapeutics IncEWTX▼ Reduced 10.0%−730K$18.1M0.11%
Centessa Pharmaceuticals PLCno ticker on file
▲ New+670.75K$16.8M0.10%
Tectonic Therapeutic IncTECX▲ Added 803%+803.4K$16.8M0.10%
Dyne Therapeutics IncDYN▲ New+813.45K$15.9M0.09%
Akero Therapeutics Incno ticker on file
▼ Sold out−324.63K$15.4M0.09%
Contineum Therapeutics IncCTNM▲ Added more than 10×+1.34M$15.4M0.09%
Nurix Therapeutics IncNRIX▲ Added 20%+776.43K$14.7M0.09%
Arcellx Incno ticker on file
▼ Sold out−166.83K$13.7M0.08%
Ventyx Biosciences Incno ticker on file
▲ Added 130%+1.33M$12M0.07%
IDEAYA Biosciences IncIDYA▲ Added 10%+343.38K$11.9M0.07%
argenx SEARGX▼ Reduced 33%−12.59K$10.6M0.06%
Viking Therapeutics IncVKTX▼ Sold out−366.08K$9.6M0.06%
Monte Rosa Therapeutics IncGLUE▼ Reduced 12%−570.36K$8.9M0.05%
Structure Therapeutics IncGPCR▼ Reduced 7.9%−123.58K$8.6M0.05%
Agios Pharmaceuticals IncAGIO▼ Sold out−189.87K$7.6M0.04%
Absci CorpABSI▲ New+2.13M$7.5M0.04%
Viridian Therapeutics IncVRDN▲ Added 13%+227.27K$7.1M0.04%
Sana Biotechnology IncSANA▼ Reduced 85%−1.72M$7M0.04%
Arcus Biosciences IncRCUS▲ New+270K$6.4M0.04%
Maplight Therapeutics IncMPLT▲ New+364.71K$6.4M0.04%
Heron Therapeutics IncHRTX▼ Sold out−4.25M$5.4M0.03%
Design Therapeutics IncDSGN▲ Added 30%+520.22K$4.9M0.03%
MBX Biosciences IncMBX▼ Sold out−277.78K$4.9M0.03%
4D Molecular TherapeuticsFDMT▲ New+475.74K$3.6M0.02%
Enliven Therapeutics IncELVN▲ Added 136%+156.57K$2.4M0.01%
Protara Therapeutics IncTARA▲ Added 81%+434.78K$2.3M0.01%
Entrada Therapeutics IncTRDA▲ Added 4.3%+206.91K$2.1M0.01%
Generation Bio Cono ticker on file
▼ Sold out−194.49K$1.2M0.01%
KALA BIO IncKALA▲ Added 83%+818.96K$455.3K0.00%
VYNE Therapeutics Incno ticker on file
▼ Sold out−851.35K$285.2K0.00%
Kiniksa Pharmaceuticals InternationalKNSA▲ Added 0.06%+1.58K$65.1K0.00%
Incyte CorpINCY▲ Added 0.00%+328$32.4K0.00%
Opthea Limitedno ticker on file
▼ Sold out−2.09M$00.00%

Holdings at the quarter's end

Baker Brothers holdings, Q4 2025
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q3 2025
1Incyte CorpINCYHealth Care17.8%$3B30.74M$98.777+ qtrs▲ Added 0.00%
2Beone Medicines LtdONC · SPONSORED ADSHealth Care15.7%$2.7B8.8M$303.817+ qtrsNo change
3Madrigal Pharmaceuticals IncMDGLHealth Care7.30%$1.2B2.14M$582.347+ qtrsNo change
4Insmed IncINSMHealth Care6.72%$1.1B6.59M$174.047+ qtrs▼ Reduced 1.7%
5Acadia Pharmaceuticals IncACAD—6.71%$1.1B42.9M$26.717+ qtrsNo change
6Celcuity IncCELC—4.62%$789.5M7.92M$99.747+ qtrsNo change
7Revolution Medicines IncRVMDHealth Care4.41%$753.1M9.46M$79.657+ qtrsNo change
8Kymera Therapeutics IncKYMRHealth Care3.94%$673.6M8.66M$77.817+ qtrs▲ Added 30%
9Summit Therapeutics IncSMMTHealth Care3.73%$636.5M36.39M$17.497+ qtrs▲ Added 7.9%
10Rhythm Pharmaceuticals IncRYTMHealth Care3.51%$599.9M5.6M$107.047+ qtrsNo change
11Kodiak Sciences IncKODHealth Care3.26%$556.9M19.92M$27.967+ qtrs▲ Added 15%
12Praxis Precision MedicinesPRAXHealth Care1.94%$332M1.13M$294.747+ qtrs▲ Added 63%
13Alkermes PLCALKS · SHSHealth Care1.64%$280.1M10.01M$27.987+ qtrs▲ Added 24%
14Grail IncGRALHealth Care1.05%$178.5M2.09M$85.595 qtrs▲ Added 28%
15Edgewise Therapeutics IncEWTXHealth Care0.96%$163.2M6.58M$24.817+ qtrs▼ Reduced 10.0%
16Arrowhead PharmaceuticalsARWRHealth Care0.85%$144.4M2.18M$66.393 qtrs▲ Added 30%
17Ionis Pharmaceuticals IncIONSHealth Care0.83%$141.8M1.79M$79.112 qtrs▲ Added 216%
18Immunovant IncIMVTHealth Care0.81%$138.7M5.46M$25.427+ qtrsNo change
19Immatics N.V.IMTX · SHS—0.74%$127M12.09M$10.507+ qtrsNo change
20IDEAYA Biosciences IncIDYA—0.73%$125.1M3.62M$34.577+ qtrs▲ Added 10%
21Roivant Sciences LtdROIV · SHSHealth Care0.71%$120.5M5.56M$21.707+ qtrs▲ Added 47%
22Abivax SAABVX · SPONSORED ADSHealth Care0.69%$118.1M875.8K$134.862 qtrsNo change
23Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL AHealth Care0.68%$116.6M2.83M$41.257+ qtrs▲ Added 0.06%
24Replimune Group IncREPL—0.63%$107.4M11.05M$9.727+ qtrsNo change
25Stoke Therapeutics IncSTOK—0.62%$105.9M3.34M$31.747+ qtrs▼ Reduced 28%
26Structure Therapeutics IncGPCR · SPONSORED ADS—0.58%$99.6M1.43M$69.556 qtrs▼ Reduced 7.9%
27Abcellera Biologics IncABCL—0.55%$94.1M27.53M$3.427+ qtrsNo change
28Nurix Therapeutics IncNRIX—0.52%$88.4M4.66M$18.977+ qtrs▲ Added 20%
29Immunocore Holdings plcIMCR · ADS—0.47%$80.6M2.32M$34.717+ qtrsNo change
30Bicycle Therapeutics PlcBCYC · SPONSORED ADS—0.45%$77.1M10.89M$7.087+ qtrsNo change
31
Crinetics Pharmaceuticalsno ticker on file
—0.45%$76.8M1.65M$46.553 qtrs▲ Added 489%
32Monte Rosa Therapeutics IncGLUE—0.40%$68.1M4.35M$15.687+ qtrs▼ Reduced 12%
33
Celcuity Incno ticker on file · NOTE 2.75% 8/1/2031
—0.39%$66.6M——2 qtrsNo change
34Ultragenyx PharmaceuticalRARE—0.37%$63.8M2.77M$23.007+ qtrsNo change
35Denali Therapeutics IncDNLI—0.36%$61.6M3.73M$16.517+ qtrsNo change
36Viridian Therapeutics IncVRDN—0.36%$61.4M1.97M$31.123 qtrs▲ Added 13%
37Entrada Therapeutics IncTRDA—0.31%$52.1M5.07M$10.287+ qtrs▲ Added 4.3%
38Rapport Therapeutics IncRAPP—0.28%$46.9M1.55M$30.343 qtrsNo change
39
Terns Pharmaceuticals Incno ticker on file
—0.23%$38.4M950K$40.401 qtrNew
40BioNTech SEBNTX · SPONSORED ADSHealth Care0.21%$35.1M368.92K$95.205 qtrsNo change
41Spyre Therapeutics IncSYREHealth Care0.19%$32.8M1M$32.763 qtrsNo change
42Dianthus Therapeutics IncDNTHHealth Care0.19%$32.5M789.76K$41.213 qtrsNo change
43Prelude Therapeutics IncPRLD—0.17%$29.4M10.12M$2.907+ qtrsNo change
44Dbv Technologies S A SponsoredDBVT · SPONSORED ADS—0.16%$28M1.46M$19.177+ qtrsNo change
45Disc Medicine IncIRON—0.16%$26.8M337.05K$79.415 qtrsNo change
46Jade Biosciences IncJBIO—0.15%$25.3M1.64M$15.431 qtrNew
47Taysha Gene Therapies IncTSHA—0.13%$22M4M$5.507+ qtrsNo change
48BioCryst Pharmaceuticals IncBCRX—0.13%$22M2.82M$7.801 qtrNew
49
Ventyx Biosciences Incno ticker on file
—0.12%$21.2M2.35M$9.032 qtrs▲ Added 130%
50argenx SEARGX · SPONSORED ADRHealth Care0.12%$21.2M25.17K$840.957+ qtrs▼ Reduced 33%
51Design Therapeutics IncDSGN—0.12%$20.9M2.23M$9.387+ qtrs▲ Added 30%
52Cerus CorpCERS—0.12%$20.6M10.01M$2.067+ qtrsNo change
53Neurogene IncNGNE—0.12%$20.4M991.69K$20.607+ qtrsNo change
54Tectonic Therapeutic IncTECX—0.11%$18.8M903.4K$20.864 qtrs▲ Added 803%
55CytomX Therapeutics IncCTMX—0.11%$18.1M4.25M$4.263 qtrsNo change
56Celldex Therapeutics IncCLDX—0.11%$18.1M665.37K$27.167+ qtrsNo change
57Xencor IncXNCR—0.10%$16.9M1.1M$15.317+ qtrsNo change
58
Centessa Pharmaceuticals PLCno ticker on file · SPONSORED ADS
—0.10%$16.8M670.75K$25.011 qtrNew
59Xenon Pharmaceuticals IncXENE—0.10%$16.6M370.21K$44.827+ qtrsNo change
60Sionna Therapeutics IncSION—0.10%$16.5M400K$41.144 qtrsNo change
61Contineum Therapeutics IncCTNM · CL A—0.10%$16.2M1.42M$11.437+ qtrs▲ Added more than 10×
62Sera Prognostics IncSERA · CLASS A COM—0.10%$16.2M5.5M$2.957+ qtrsNo change
63Dyne Therapeutics IncDYN—0.09%$15.9M813.45K$19.561 qtrNew
64Alumis IncALMS—0.09%$15.3M1.56M$9.767+ qtrsNo change
65
Nuvalent Incno ticker on file
—0.09%$14.5M143.94K$100.593 qtrsNo change
66Pharvaris N VPHVS—0.06%$10.4M375K$27.752 qtrsNo change
67Relay Therapeutics IncRLAY—0.06%$9.8M1.16M$8.467+ qtrsNo change
68Absci CorpABSI—0.04%$7.5M2.13M$3.491 qtrNew
69Arcus Biosciences IncRCUS—0.04%$6.4M270K$23.831 qtrNew
70Maplight Therapeutics IncMPLT—0.04%$6.4M364.71K$17.561 qtrNew
71vTv Therapeutics IncVTVT · CL A—0.04%$5.9M148.31K$39.997+ qtrsNo change
72Wave Life Sciences LtdWVE · SHS—0.03%$5.8M344.06K$17.006 qtrsNo change
73Sagimet Biosciences IncSGMT—0.03%$5.6M953K$5.927+ qtrsNo change
74Protara Therapeutics IncTARA—0.03%$5.2M971.61K$5.337+ qtrs▲ Added 81%
75LB Pharmaceuticals IncLBRX—0.03%$4.5M200K$22.262 qtrsNo change
76Enliven Therapeutics IncELVN—0.02%$4.2M271.41K$15.407+ qtrs▲ Added 136%
774D Molecular TherapeuticsFDMT—0.02%$3.6M475.74K$7.501 qtrNew
78Vir Biotechnology IncVIR—0.02%$3.3M542.54K$6.035 qtrsNo change
79TScan Therapeutics IncTCRX—0.02%$2.8M2.78M$1.007+ qtrsNo change
80Sana Biotechnology IncSANA—0.01%$1.3M310.48K$4.077+ qtrs▼ Reduced 85%
81Skye Bioscience IncSKYE—0.01%$1.1M1.45M$0.74977+ qtrsNo change
82KALA BIO IncKALA—0.01%$1M1.8M$0.55597+ qtrs▲ Added 83%
83Aligos Therapeutics IncALGS—0.01%$774.1K83.06K$9.327+ qtrsNo change
84Tyra Biosciences IncTYRA—0.00%$278.9K10.61K$26.297+ qtrsNo change
85Acrivon Therapeutics IncACRV—0.00%$55K22.81K$2.417+ qtrsNo change
86
Surrozen Incno ticker on file · W EXP 8/11/2026
—0.00%$16.7K833.33K$0.02007+ qtrsNo change

By sector

Baker Brothers portfolio by sector, Q4 2025
SectorShare of portfolioValuePositions
Health Care77.2%$13.2B23
No sector on file22.8%$3.9B63

Questions and answers

What did Baker Brothers own in Q4 2025?

Baker Bros. Advisors's 13F for Q4 2025 lists 86 positions worth $17.1B. The largest: INCY (17.8%), ONC (15.7%), MDGL (7.3%), INSM (6.7%), ACAD (6.7%).

What did Baker Brothers buy in Q4 2025?

The largest purchases, by the shares bought at the quarter-end price the filing implies: KYMR (added, $156.1M), PRAX (added, $128.8M), IONS (added, $96.9M), KOD (added, $72.9M), Crinetics Pharmaceuticals (added, $63.7M), ALKS (added, $53.7M).

What did Baker Brothers sell in Q4 2025?

The largest sales: Merus N V (sold out, $54.1M), NTLA (sold out, $47.4M), STOK (reduced, $41.2M), Avidity Biosciences Inc (sold out, $27.2M), PCVX (sold out, $23.1M), Cidara Therapeutics Inc (sold out, $21.8M).

When was this filing made?

Baker Bros. Advisors filed its 13F for the quarter ending Dec 31, 2025 on Feb 17, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Baker Brothers portfolio, Q4 2025: Baker Bros. Advisors 13F holdings”, data as of 17 February 2026. https://funkfolio.com/gurus/baker-brothers/2025-q4

Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Dec 31, 2025.

Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Dec 31, 2025, filed Feb 17, 2026. Changes compare share counts with the filing for Sep 30, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $17.1B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 7 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.